← All trials
NCT06551142
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 30, 2024
- Primary completion
- Dec 21, 2026
- Completion date
- Jun 9, 2027
- First posted
- Aug 13, 2024
- Last posted
- Aug 30, 2024
- Enrollment
- 260
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GlaxoSmithKlineLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.